POZ - Treatment News : Tenofovir Linked to Mild Decrease in Kidney Function, but Not Kidney Disease

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » October 2008

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


email print

October 3, 2008

Tenofovir Linked to Mild Decrease in Kidney Function, but Not Kidney Disease

People taking a regimen that contains tenofovir (found in Viread, Truvada and Atripla) were more likely to experience mild decreases in kidney function over 144 weeks of treatment than people taking other antiretrovirals (ARVs), but they were no more likely to have serious kidney problems, according to a study published in the October 18 issue of AIDS.

Although clinical trials have not found higher rates of kidney disease among patients using tenofovir, several large cohort studies have found higher rates of mild reductions in a measure of kidney function called the glomerular filtration rate (GFR)—a sign of possible kidney problems—in tenofovir-treated patients compared with those using other nucleoside/nucleotide reverse transcriptase inhibitors.

To better determine tenofovir’s impact on kidney function, Joel Gallant, MD, from the Johns Hopkins University School of Medicine in Baltimore, and his colleagues combined and reanalyzed data from two Gilead Sciences-sponsored clinical trials, called 903 and 934. The analysis included 1,111 patients; 556 received an ARV regimen containing tenofovir, and 555 patients received a regimen containing either Zerit (stavudine) or Retrovir (zidovudine).

Dr. Gallant’s team found that the patients taking tenofovir were more likely to have small decreases in GFR, while those taking either Zerit or Retrovir were more likely to experience small increases. Generally, the decreases in GFR in patients taking tenofovir occurred within the first 96 weeks of treatment and did not progress to serious kidney disease. The difference in GFR between those on tenofovir versus other treatments was statistically significant, meaning that the difference was too large to have occurred by chance. The decrease in GFR in those on tenofovir, however, was so small that it is unlikely to cause symptoms or progress to kidney disease, and people on tenofovir were no more likely to experience serious kidney toxicity or to stop treatment due to kidney troubles than people taking Zerit or Retrovir.

Search: kidney, glomular filtration rate, GFR, tenofovir, Viread, Truvada, Atripla, Zerit, stavudine, Retrovir, zidovudine


Scroll down to comment on this story.

email print

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

         


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar
Starting Treatment
Quilt in the Capital
POZ Army


    CuteBoyinQns
    Jackson Heights
    New York


    sequoiamv
    San Jose
    California


    vinamarino94
    new york city
    New York


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Talk to Us
Poll
Do you support rapid in-home HIV testing?
Yes
No

Survey
Health 2.0

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.